CDKN2 refers to a family of genes that encode cyclin-dependent kinase (CDK) inhibitors, which are critical regulators of the cell cycle.
The most clinically significant member is CDKN2A, often referred to simply as CDKN2.
This family of genes act as tumor suppressors by preventing cells from dividing too rapidly or in an uncontrolled manner.
CDKN2A single gene uniquely produces two distinct proteins using different frames.
p16: Inhibits CDK4 and CDK6, maintaining the retinoblastoma (Rb) protein in an active state to block the transition from the G1 to S phase of the cell cycle.
p14ARF: Protects the p53 protein from degradation, allowing p53 to initiate cell cycle arrest or apoptosis (cell death) in response to DNA damage.
Other Family Members: Include CDKN2B (p15), CDKN2C (p18), and CDKN2D (p19), which all function as inhibitors of CDK4/6.
CDKN2A is the second most commonly inactivated gene in human cancers after p53.
Familial Melanoma: Inherited (germline) mutations in CDKN2A are found in up to 40% of families with a history of melanoma.
Pancreatic Cancer: Mutations are strongly associated with Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome, significantly increasing the risk of pancreatic cancer.
Somatic Mutations: Acquired mutations or deletions are frequently found in a wide range of cancers, including:
Glioblastoma Bladder Cancer. Acute Lymphoblastic Leukemia (ALL) Head and neck squamous cell carcinoma.
CDKN2A expression increases as cells age and is a primary driver of cellular senescence/permanent growth arrest.
CDKN2A is often used as a biological marker for physiological age.
Testing for CDKN2A mutations is recommended for families meeting specific criteria, such as multiple relatives with melanoma or pancreatic cancer.
Treatment Biomarker: Low levels of p16 can sometimes predict a better response to CDK4/6 inhibitors (like palbociclib), while high levels may indicate resistance.